Results 21 to 30 of about 10,095 (153)
Asian Pacific Journal of Tropical Biomedicine, 2016 Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line.
Seyed Ataollah Sadat Shandiz +9 more
doaj +1 more source
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity
Turkish Journal of Hematology, 2015 Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.
Caterina Musolino +7 more
doaj +1 more source
Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate [PDF]
Vojnosanitetski Pregled, 2013 Introduction. Gastrointestinal stromal tumors (GISTs) are rare and account for 0.1%-3% of all gastrointestinal neoplasms. GISTs are most commonly located in the stomach (60%) and 20%-25% are malignant, with metastases involving the peritoneum or
Čolović Radoje +5 more
doaj +1 more source
Jurnal Penyakit Dalam Indonesia, 2020 Introduction. The complete hematologic response is an integral part to achieve the complete cytogenetic response target and the major molecular response of imatinib mesylate therapy, although it does not determine the prognosis.
Ikhwan Rinaldi +1 more
doaj +1 more source
OncoImmunology, 2018 Several studies support the notion that the kinase inhibitor Imatinib mesylate exerts off-target effects on cells of the immune system. After our first report of continuous daily oral administration in subjects with relapsed/refractory neuroblastoma (NB,
Fabio Morandi +12 more
doaj +1 more source
Veterinární Medicína, 2019 A seven-year-old Toy Poodle was presented for progressive ataxia and seizure episodes. Magnetic resonance imaging revealed inflammatory lesions in the cerebrum and brainstem.
Joong Hyun Song +6 more
doaj +1 more source
Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia
Eurasian Journal of Medicine, 2019 Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak +6 more
doaj +1 more source
American Journal of Experimental and Clinical Research, 2014 A unique case of a 50-year-old Japanese male with jejunal leiomyosarcoma (LMS) who subsequently developed gastrointestinal stromal tumor (GIST) and desmoid tumor (DT) during five years and six months after the initial surgery is reported. The patient was
Yuji Kurihara +2 more
doaj +2 more sources
AIChE Journal, Volume 72, Issue 7, July 2026.Abstract In pharmaceutical industries, continuous manufacturing methods have already been well established to improve productivity and process intensification. However, to better understand the trade‐offs of continuous crystallizers over the existing batch production systems, a robust technoeconomic cost and sustainability analysis is necessary to ...
Jungsoo Rhim, Zoltan K. Nagy
wiley +1 more source
Haematologica, 2011 Background Incubation of chronic myeloid leukemia cells in hypoxia inhibits growth and selects BCR/Abl-independent cells with stem cell properties which are refractory to imatinib-mesylate.
Serena Giuntoli +5 more
doaj +1 more source